Endocarditis following ocrelizumab in relapsing-remitting MS

  • Ocrelizumab is a monoclonal anti-CD20 antibody targeting B cells, which is authorized for relapsing-remitting MS (RRMS) and active primary progressive MS. Here, we report, to the best of our knowledge, the first case of infective endocarditis in a patient treated with ocrelizumab.

Download full text files

Export metadata

Additional Services

Share in Twitter Search Google Scholar
Metadaten
Author:Simon Raoul FaissnerORCiDGND, Carolin SchwakeORCiDGND, Michael GotzmannORCiDGND, Andreas MüggeORCiDGND, Stephan SchmidtGND, Ralf GoldORCiDGND
URN:urn:nbn:de:hbz:294-77420
DOI:https://doi.org/10.1212/NXI.0000000000000680
Parent Title (English):Neurology: Neuroimmunology & Neuroinflammation
Publisher:American Academy of Neurology
Place of publication:Minneapolis
Document Type:Article
Language:English
Date of Publication (online):2020/12/29
Date of first Publication:2020/02/03
Publishing Institution:Ruhr-Universität Bochum, Universitätsbibliothek
Tag:Open Access Fonds
Volume:7
Issue:3
First Page:1
Last Page:4
Note:
Article Processing Charge funded by the Deutsche Forschungsgemeinschaft (DFG) and the Open Access Publication Fund of Ruhr-Universität Bochum.
Institutes/Facilities:St. Josef-Hospital Bochum, Neurologische Klinik
St. Josef-Hospital Bochum, Medizinische Klinik II, Klinik für Kardiologie
Dewey Decimal Classification:Technik, Medizin, angewandte Wissenschaften / Medizin, Gesundheit
open_access (DINI-Set):open_access
Licence (English):License LogoCreative Commons - CC BY-NC-ND 4.0 - Attribution-NonCommercial-NoDerivatives 4.0 International

OPUS4 Logo